Synthena AG is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of RNA. Its proprietary tricyclo-DNA technology platform offers broad advantages over state of the art oligonucleotide chemistries for new RNA intervention strategies like splice switching, and other antisense approaches. Its most advanced preclinical drug development program focuses on Duchenne Muscular Dystrophy, a genetic disorder which affects 1/3,500 boys and which leads to death in early adulthood. Modulation of RNA for therapeutic purposes holds the promise of opening up entirely new concepts for pharmaceutical intervention, however, current oligonucleotide chemistries to modulate RNA do not meet the requirements for efficient delivery, pharmacokinetics and tolerability. Synthena's mission is to establish its proprietary tricyclo-DNA technology as the leading platform for RNA modulation.
| Website | http://www.synthena.com |
| Employees | View employees |
| Address | 3 Freiestrasse, Bern, Bern 3012, CH |
| Phone | +41 31 631 42 65 |
| Fax | +41 31 631 34 22 |
| Industry | Business Services General, Biotechnology, Business Services, Science and Engineering, Medical, Health Care |
| Competitors | abcam, Thermo Fisher Scientific, Merck Group, GenScript, PEPROTECH EC LTD, R&D Systems, Cell Signaling Technology (CST), Bio-Techne, MilliporeSigma, Atkore +38 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies |
Looking for a particular Synthena AG employee's phone or email?
Synthena AG Questions
Synthena AG is based in Bern, Bern.
The NAICS codes for Synthena AG are [54, 541713, 5417, 54171, 541].
The SIC codes for Synthena AG are [873, 87].
